Mutation analysis of TP53 in colorectal cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Clicks: 183
ID: 277479
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
183 views
45 readers
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aim: Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The present study was aimed to reveal the mutation at TP53 in Peshawar Pakistan.
Material and methods: For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire. The polymerase chain reaction was performed.
Results: The results of the present study have revealed that the ratio of colorectal cancer in males is higher 62% than females (38%). Histopathological results have indicated that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 colorectal cancer patients. The nucleotide sequence of the human TP53 gene of colorectal cancer patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.
Conclusion: The present study concluded that point mutations were found in exons 5&7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to colorectal cancer patients having no mutations.
Material and methods: For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire. The polymerase chain reaction was performed.
Results: The results of the present study have revealed that the ratio of colorectal cancer in males is higher 62% than females (38%). Histopathological results have indicated that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 colorectal cancer patients. The nucleotide sequence of the human TP53 gene of colorectal cancer patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.
Conclusion: The present study concluded that point mutations were found in exons 5&7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to colorectal cancer patients having no mutations.
| Reference Key |
kakakhel2021mutationazastanny
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kakakhel, Mian Adnan;Ali, Ihsan;Fayyaz, Aamna;Anwar, Zahid;Saif, Irfan;Khan, Ikram;Jahangir, Muhammad; |
| Journal | Ķazaķstannyṇ Klinikalyķ Medicinasy |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.